Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: A children's Oncology group report

Journal of Clinical Oncology

Volumn 27, Issue 9, 2009, Pages 1456-1461

  Cole, Peter D ^a   Schwartz, Cindy L ^a   Drachtman, Richard A ^a   De Alarcon, Pedro A ^a   Chen, Lu ^a   Trippett, Tanya M ^a  

^a CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GEMCITABINE; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; LIVER ENZYME; NAVELBINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; VINBLASTINE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; EDEMA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GLUCOSE BLOOD LEVEL; HEADACHE; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTENSION; HYPOXIA; INFECTION; LIMB PAIN; LUNG DIFFUSION CAPACITY; LUNG INFILTRATE; MALE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RECURRENT CANCER; SCHOOL CHILD; SECOND CANCER; SENSORY NEUROPATHY; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; THROMBUS; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HODGKIN DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 63049134801     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.3778     Document Type: Article

References (65)

1. Lieskovsky YE, Donaldson SS, Torres MA, et al: High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: Results and prognostic indices. J Clin Oncol 22:4532-4540, 2004
2. Lavoie JC, Connors JM, Phillips GL, et al: High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long-term outcome in the first 100 patients treated in Vancouver. Blood 106:1473-1478, 2005
3. Josting A: Autologous transplantation in relapsed and refractory Hodgkin's disease. Eur J Haematol Suppl 141-145, 2005
4. Hagemeister FB, Tannir N, McLaughlin P, et al: MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5:556-561, 1987
5. Plunkett W, Huang P, Xu YZ, et al: Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10, 1995
6. Santoro A, Bredenfeld H, Devizzi L, et al: Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 18:2615-2619, 2000
7. Zinzani PL, Bendandi M, Stefoni V, et al: Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 85:926-929, 2000
8. Toh HC, Sun L, Koh CH, et al: Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: A comparison with vincristine. Leuk Lymphoma 31:195-208, 1998
9. Rule S, Tighe M, Davies S, et al: Vinorelbine in the treatment of lymphoma. Hematol Oncol 16:101-105, 1998
10. Devizzi L, Santoro A, Bonfante V, et al: Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 5:817-820, 1994
11. Devizzi L, Santoro A, Bonfante V, et al: Vinorelbine: A new promising drug in Hodgkin's disease. Leuk Lymphoma 22:409-414, 1996
12. Herbst RS, Lynch C, Vasconcelles M, et al: Gemcitabine and vinorelbine in patients with advanced lung cancer: Preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol 48: 151-159, 2001
13. Bajetta E, Chiara Stani S, De Candis D, et al: Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial. Cancer 89:763-768, 2000
14. Beretta GD, Michetti G, Belometti MO, et al: Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br J Cancer 83:573-576, 2000
15. Camps C, Martinez EN, Jaime AB: Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: A pilot study. Lung Cancer 27:47-53, 2000
16. Chen YM, Perng RP, Yang KY, et al: A multi-center phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer. Chest 117:1583-1589, 2000
17. Esteban E, Fra J, Corral N, et al: Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. Invest New Drugs 20:73-82, 2002
18. Feliu J, Lopez Gomez L, Madronal C, et al: Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin: Oncopaz Cooperative Group. Cancer 86:1463-1469, 1999
19. Frasci G, Lorusso V, Panza N, et al: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529-2536, 2000
20. Gridelli C, Cigolari S, Gallo C, et al: Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non - small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 31:277-284, 2001
21. Gridelli C, Frontini L, Perrone F, et al: Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: A phase II study of three different doses - Gem Vin Investigators. Br J Cancer 83:707-714, 2000
22. Hirsh V, Langleben A, Ayoub J, et al: Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: A phase II multicenter trial. Cancer 92:830-835, 2001
23. Herbst RS, Khuri FR, Lu C, et al: The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: Potential for decreased toxicity and combination with biological therapy. Cancer 95:340-353, 2002
24. Kawasaki Y, Kato K, Kobayashi K, et al: Successful outpatient treatment with chemotherapy of weekly gemcitabine and vinorelbine for a patient with recurrent lung cancer. Gan to Kagaku Ryoho 29:107-109, 2002
25. Kawasaki Y, Koshohbu T, Nakatani S, et al: Successful treatment with chemotherapy of vinorelbine and gemcitabine for an elderly patient with advanced non-small cell lung cancer. Gan to Kagaku Ryoho 30:515-517, 2003
26. Krajnik G, Mohn-Staudner A, Thaler J, et al: Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC phase II trial - Austrian Association for the Study of Lung Cancer. Ann Oncol 11:993-998, 2000
27. Laack E, Mende T, Benk J, et al: Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: A phase II trial. Eur J Cancer 37:583-590, 2001
28. Lilenbaum R: Options in advanced non-small cell lung cancer: A review and report on a phase II study of vinorelbine plus gemcitabine. Oncologist 6:16-19, 2001
29. Lilenbaum R, Cano R, Schwartz M, et al: Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: A phase II study. Cancer 88: 557-562, 2000
30. Lorusso V, Crucitta E, Panza N, et al: Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer. Ann Oncol 13:1862-1867, 2002
31. Hortobagyi GN: Treatment of advanced breast cancer with gemcitabine and vinorelbine. Oncology (Huntington) 15:15-17, 2001
32. Hortobagyi GN: Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer. Clin Breast Cancer 3:34-38, 2002
33. Lobo F, Virizuela JA, Dorta FJ, et al: Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: Results of a phase II trial. Clin Breast Cancer 4:46-50, 2003
34. Nicolaides C, Dimopoulos MA, Samantas E, et al: Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 11:873-875, 2000
35. Sanal SM, Gokmen E, Karabulut B, et al: Gemcitabine and vinorelbine combination in patients with metastatic breast cancer. Breast J 8:171-176, 2002
36. Stathopoulos GP, Rigatos SK, Pergantas N, et al: Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 20:37-41, 2002
37. Valenza R, Leonardi V, Gebbia V, et al: Gemcitabine and vinorelbine in pretreated advanced breast cancer: A pilot study. Ann Oncol 11:495-496, 2000
38. Grunewald R, Kantarjian H, Du M, et al: Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406-413, 1992
39. Grunewald R, Abbruzzese JL, Tarassoff P, et al: Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258-262, 1991
40. Abbruzzese J, Grunewald R, Weeks E, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
41. Touroutoglou N, Gravel D, Raber MN, et al: Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9:1003-1008, 1998
42. Patel SR, Gandhi V, Jenkins J, et al: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483-3489, 2001
43. Sezer O, Eucker J, Jakob C, et al: Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine. Invest New Drugs 19:101-104, 2001
44. Akrivakis K, Schmid P, Flath B, et al: Prolonged infusion of gemcitabine in stage IV breast cancer: A phase I study. Anticancer Drugs 10:525-531, 1999
45. Schmid P, Akrivakis K, Flath B, et al: Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10:625-631, 1999
46. Pollera CF, Ceribelli A, Crecco M, et al: Prolonged infusion gemcitabine: A clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels. Invest New Drugs 15:115-121, 1997
47. Tempero M, Plunkett W, ruiz van Haperen V, et al: Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 18:273a, 1999 (abstr 1048)
48. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
49. [Erratum: J Clin Oncol 8:1602, 1990]
50. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
51. Laack E, Dickgreber N, Muller T, et al: Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non - small-cell lung cancer: From the German and Swiss Lung Cancer Study Group. J Clin Oncol 22:2348-2356, 2004
52. Lorusso V, Carpagnano F, Frasci G, et al: Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non - small-cell lung cancer. J Clin Oncol 18:405-411, 2000
53. Spencer A, Arthur C, Schwarer AP: Vinorelbine and gemcitabine with filgrastim (VGF) support shows significant activity against advanced lymphoma. Proc Am Soc Hematol 100:781a, 2002 (abstr 3088)
54. Hamlin PA, Kewalramani T, Schaindlin P, et al: Gemicitabine/vinorelbine: A well tolerated and effective regimen for patients with relapsed/refractory Hodgkin's disease (HD) who fail autologous stem cell transplantation (ASCT). Proc Am Soc Hematol 100:634a, 2002 (abstr 2498)
55. Spencer A, Reed K, Arthur C: Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 37:760-766, 2007
56. Ozkaynak MF, Jayabose S: Gemcitabine and vinorelbine as a salvage regimen for relapse in Hodgkin lymphoma after autologous hematopoietic stem cell transplantation. Pediatr Hematol Oncol 21:107-113, 2004
57. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
58. Aapro MS, Martin C, Hatty S: Gemcitabine: A safety review. Anticancer Drugs 9:191-201, 1998
59. Briasoulis E, Pavlidis N: Noncardiogenic pulmonary edema: An unusual and serious complication of anticancer therapy. Oncologist 6:153-161, 2001
60. Schwartz BM, Khuntia D, Kennedy AW, et al: Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy. Gynecol Oncol 91:421-422, 2003
61. Friedlander PA, Bansal R, Schwartz L, et al: Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer 100:1793-1799, 2004
62. Fakih MG: Gemcitabine-induced rectus abdominus radiation recall. JOP 7:306-310, 2006
63. Saif MW, Sellers S, Russo S: Gemcitabine-related radiation recall in a patient with pancreatic cancer. Anticancer Drugs 17:107-111, 2006
64. Schwarte S, Wagner K, Karstens JH, et al: Radiation recall pneumonitis induced by gemcitabine. Strahlenther Onkol 183:215-217, 2007
65. Vogl DT, Glatstein E, Carver JR, et al: Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation. Leuk Lymphoma 46:1313-1320, 2005